Cannabinoid modulation of dynorphin A: Correlation to cannabinoid-induced antinociception

European Journal of Pharmacology

Volumn 378, Issue 3, 1999, Pages 237-248

  Mason Jr , David J ^a   Lowe, John ^b   Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

9 Tetrahydrocannabinol; Anandamide; Antinociception; CP55,940; Dynorphin A; Opioid; SR141716A; Tail flick latency

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; DYNORPHIN A; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN; NORBINALTORPHIMINE; OPIATE RECEPTOR; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; AUTORADIOGRAPHY; CEREBROSPINAL FLUID; CHRONIC PAIN; CONTROLLED STUDY; INTRATHECAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SPINAL ANESTHESIA; TAIL FLICK TEST;

ANALGESICS; ANIMALS; CANNABINOIDS; CYCLOHEXANOLS; DIMETHYL SULFOXIDE; DYNORPHINS; INJECTIONS, SPINAL; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NOCICEPTORS; PAIN; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL;

EID: 0345540636     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00479-3     Document Type: Article

References (60)

1. Basbaum A.I., Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 7:1984;309-388.
2. Besse D., Lombard M.C., Zajac J.M., Roques B.P., Besson J.M. Pre- and postsynaptic distribution of μ, δ and κ opioid receptors in the superficial layers of the cervical dorsal horn of the spinal cord. Brain Res. 521:1990;15-22.
3. Chavkin C., James I., Goldstein A. Dynorphin is a specific endogenous ligand for the kappa opioid receptor. Science. 215:1992;413-415.
4. Chou J.Z., Chait B.T., Wang R., Kreek M.J. Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo. Peptides. 17(6):1996;983-990.
5. Collins D.R., Pertwee R.G., Davies S.N. Prevention by the cannabinoid antagonist, SR 141716A, of cannabinoid mediated blockade of long term potentiation in the rat hippocampal slice. Br. J. Pharmacol. 115:1995;869-870.
6. 8-tetrahydrocannabinol. J. Med. Chem. 33:1990;1437-1443.
7. Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmaceutical profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260:1991;201-209.
8. Corbett A.D., Patterson S.J., McKnight A.T., Morgan J., Kosterlitz H.W. Dynorphin (1-8) and dynorphin (1-9) are ligands for the kappa subtype of opiate receptors. Nature. 299:1982;79-81.
9. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
10. Devane W.A., Dysarz I., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
11. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
12. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-175.
13. 9 tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur. J. Pharmacol. 12:1970;382-384.
14. 5]enkephalin from dynorphin A (1-8) by rat central nervous tissue in vitro. J. Neurochem. 54:1990;1379-1385.
15. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1955;1096-1121.
16. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor mediated signal transduction. Cell Biol. 90:1993;7656-7660.
17. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
18. Fujimoto J.M., Arts K.S., Rady J.J., Tseng L.F. Spinal dynorphin A (1-17). Possible mediator of antianalgesic action. Neuropharmacology. 29:1990;609-617.
19. Harris L.S., Pierson A.K. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143:1990;141-148.
20. Hayes A.G., Birch P.J., Hayward N.J., Sheehan M.J., Rofers H., Tyers M.B., Judd D.B., Scopes D.I.C., Naylor A. A series of novel, highly potent and selective agonists for the κ-opioid receptor. Br. J. Pharmacol. 101:1990;944-948.
21. Horan P., Taylor J., Yamamura H.I., Porreca F. Extremely long lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J. Pharmacol. Exp. Ther. 260:1992;1237-1243.
22. Howlett A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 35:1984;1803-1810.
23. Howlett A.C., Flemming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26:1984;532-538.
24. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
25. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgesics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33:1988;297-302.
26. Howlett, A.C., Evans, D.M., Houston, D.B., 1992. The cannabinoid receptor. In: Murphy, L., Burke, A. (Eds.), Neurobiology and Neurophysiology, pp. 35-72.
27. Hunter J.C., Leighton G.E., Meecham K.G., Boyle S.J., Horwell D.C., Rees D.C., Hughes J. CI-977, a novel and selective agonist for the κ-opioid receptor. Br. J. Pharmacol. 101:1990;183-189.
28. 2 noradrenergic mechanism. Brain Res. 559(2):1991;309-314.
29. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40(3):1991;471-478.
30. Matsuda L.A., Lolait S.J., Bowstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
31. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., Howlett A.C. Structure-activity relationships for cannabinoid receptor binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44:1993;1008-1015.
32. Morris B.J., Herz A. Simultaneous down-regulation of κ binding sites and up regulation of μ binding sites following chronic agonist/antagonist treatment. Adv. Biol. Sci. 75:1989;691-694.
33. Muller S., Grand B.L., Huchaus G. Metabolism of dynorphin A 1-13 in human cerebrospinal fluid. Neurochem. Res. 21(10):1997;1213-1219.
34. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
35. Nishiyama K., Kwak S., Murayama S., Kanazawa I. Substance P is a possible neurotransmitter in the rat spinothalamic tract. Neurosci. Res. 12:1995;261-266.
36. Nylander I., Tan-No K., Winter A., Silberring J. Processing of prodynorphin-derived peptides in striatal extracts, identification by electrospray ionization mass spectrometry linked to size-exclusion chromatography. Life Sci. 57(2):1995;123-129.
37. 9-THC and the cannabimimetic agents, CP55,940, WIN 55,212 and anandamide. Br. J. Pharmacol. 110:1993;1483-1490.
38. Portoghese P.S., Nagase H., Lipkowski A.W., Larson D.L., Takemori A.E. Binaltorphimine-related bivalent ligands and their k opioid receptor antagonist selectivity. J. Med. Chem. 31:1988;836-841.
39. 9-THC and morphine in the spinal cord. J. Pharmacol. Exp. Ther. 279:1996;608-616.
40. Pugh G.J., Mason D.J., Combs V., Welch S.P. Involvement of dynorphin B in the antinociceptive effects of CP55,940, in the spinal cord. J. Pharmacol. Exp. Ther. 281:1997;730-737.
41. Rady J.J., Fujimoto J.M., Tseng L.F. Dynorphins other than dynorphin lack spinal antianalgesic activity but do act on dynorphin A (1-17) receptors. J. Pharmacol. Exp. Ther. 259:1991;1073-1079.
42. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., LeFur G. SR141716A, a potent and selective antagonist of the cannabinoid receptor. Fed. Eur. Biochem. Soc. Lett. 350:1994;240-244.
43. Rinaldi-Carmona M., Barth F., Millan J., Deroq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284(2):1998;644-650.
44. 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 51:1995;731-737.
45. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., LeFur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
46. 9-tetrahydrocannabinol-induced analgesia. Brain Res. 578:1992;8.
47. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
48. Thomas, B.F., Gilliam, A.F., Burch, D.F., Roche, M.J., Seltzman, H.H., 1997. Comparative binding analysis of cannabinoid agonists and antagonists: evidence supporting neuronal cannabinoid receptor subtypes. Int. Cann. Res. Soc. Symp. Cann.
49. Tseng L.F. Intracerebroventricular administration of beta-endorphin releases immunoreactive methionine enkephalin from the spinal cord of cats, guinea pigs and mice. Neuropharmacology. 28:1989;1333-1339.
50. Turkanis S.A., Karler R. Changes in neurotransmitter release at a neuromuscular junction of the lobster caused by cannabinoids. Neuropharmacology. 22(7):1988;737-742.
51. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
52. Welch S.P. Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol. Biochem. Behav. 49:1994;929-934.
53. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend. 45:1997;39-45.
54. 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273:1995;1235-1244.
55. Wiley J.L., Barrett R.L., Lowe J., Balster R.L., Martin B.R. Discriminative effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:1995;669-676.
56. 9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995;16.
57. Yaksh T.L. The antinociceptive effect of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;334340.
58. Yasuda K., Raynor K., Haeyoung K., Breder C.D., Takeda J., Reisine T., Bell G.I. Cloning and functional comparison of k and d opioid receptors from mouse brain. Neurobiology. 90:1993;67366740.
59. Zachariou V., Goldstein B.D. Kappa-opioid receptor modulation of the release of substance P in the dorsal horn. Brain Res. 706(1):1996;80-88.
60. Zachariou V., Goldstein B.D. Dynorphin-(1-8) inhibits the release of substance P-like immunoreactivity in the spinal cord of rats following a noxious mechanical stimulus. Eur. J. Pharmacol. 323:1997;159-165.